Deciphera Pharmaceuticals Inc
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in I… Read more
Deciphera Pharmaceuticals Inc (D05) - Total Liabilities
Latest total liabilities as of March 2024: €104.88 Million EUR
Based on the latest financial reports, Deciphera Pharmaceuticals Inc (D05) has total liabilities worth €104.88 Million EUR as of March 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Deciphera Pharmaceuticals Inc - Total Liabilities Trend (2016–2023)
This chart illustrates how Deciphera Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Deciphera Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Deciphera Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Keda Clean Energy Co Ltd
SHG:600499
|
China | CN¥14.23 Billion |
|
Shanghai Kingstar Winning Software
SHE:300253
|
China | CN¥2.61 Billion |
|
Hui Lyu Ecological Technology Groups Co Ltd
SHE:001267
|
China | CN¥1.88 Billion |
|
Oberbank AG
VI:OBS
|
Austria | €24.67 Billion |
|
OliX PharmaceuticalsInc
KQ:226950
|
Korea | ₩44.02 Billion |
|
Indra Sistemas S.A
OTCGREY:ISMAF
|
USA | $5.03 Billion |
|
Sumitomo Rubber Industries Ltd
F:108
|
Germany | €693.72 Billion |
Liability Composition Analysis (2016–2023)
This chart breaks down Deciphera Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Deciphera Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Deciphera Pharmaceuticals Inc (2016–2023)
The table below shows the annual total liabilities of Deciphera Pharmaceuticals Inc from 2016 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €122.65 Million | +9.17% |
| 2022-12-31 | €112.35 Million | -9.95% |
| 2021-12-31 | €124.76 Million | +26.34% |
| 2020-12-31 | €98.76 Million | +30.04% |
| 2019-12-31 | €75.94 Million | +113.45% |
| 2018-12-31 | €35.58 Million | +135.27% |
| 2017-12-31 | €15.12 Million | -92.39% |
| 2016-12-31 | €198.71 Million | -- |